Objective To study the effect of survivin on proliferation and invasion of glioma cells treated by bevacizumab (Bev). Methods The human spongioblastoma cell line U87 was routinely cultured in vitro; the growth rates of U87 cells after 0, 2, 4, 6, 8 and 10 mg/mL Bev treatment for 2, 4 and 6 d were determined by MTT assay. The specific shRNA vectors (pRNAT, pRNAT-survivin shRNA, pRNAT-NS si) were transfected into U87 cells; U87, U87/sur(-), U87/pCtrl and U87/NS si cells were cultured for one d, and then, they were divided into 6 groups: U87 cells without Bev treatment, U87/sur (-) cells without Bev treatment, U87 cells with Bev treatment, U87/sur (-) cells with Bev treatment, U87/pCtrl cells with Bev treatment and U87/NS si cells with Bev treatment; 6 mg/mL Bev was given to each Bev treatment group. The cell invasion capacity was determined by Traswell assay; the cell movement and migratory capacities were detected by wound-healing assay, and the cell proliferation was determined by MTT assay. Results The cells treated by Bev at concentrations of 0, 2, 4, or 6 mg/mL exhibited similar viability (P>0.05), while the cells treated by Bev at concentrations of 8 or 10 mg/mL showed significantly decreased viability as compared with cells treated by Bev at concentration of 0 mg/mL (P<0.05). As compared with U87 cells with Bev treatment, U87/sur(-) cells with Bev treatment had significantly decreased viability (P<0.05); U87/sur (-) cells with Bev treatment had significantly decreased viability as compared with U87/sur(-) cells without Bev treatment (P<0.05); as compared with that in the U87 cells without Bevb treatment, the migration distance in the U87 cells with Bev treatment was significantly longer (P<0.05). As compared with that in the U87 cells without Bev treatment, the migration distance in the U87/sur (-) cells with Bev treatment was significantly shorter (P<0.05); as compared with that in the U87 cells without Bev treatment, the number of cells invading into the lower chamber in the U87 cells with Bev treatment was significantly larger (P<0.05); as compared with that in the U87 cells without Bev treatment, the the number of cells invading into the lower chamber in the U87/sur(-) cells with Bev treatment was significantly smaller (P<0.05). Conclusion Down-regulation of survivin could suppress glioma cells invasion induced by Bev treatment, and synergistic effect is observed between down-regulation of survivin and Bev treatment in suppressing the viability of glioma cells.